The human tumor clonogenic assay used to study ovarian cancers

  • Charles E. Welander
Part of the Cancer Treatment and Research book series (CTAR, volume 23)


During the last decade, the treatment of ovarian cancer has changed markedly as the available armamentarium of cytotoxic drugs has improved. It remains apparent that surgical cytoreduction (debulking) procedures are useful, particularly in those cases where the largest mass of residual tumor can be reduced to less than 1 cm in size [1]. However, even more important than the degree of surgical debulking which can be achieved is the apparent improvement in clinical response rates seen with new innovations in chemotherapy. The Gynecologic Oncology Group (GOG) conducted a large randomized trial between 1976 and 1979 of suboptimal (> 3 cm tumor bulk) untreated ovarian cancers (Protocol #22), which showed that melphalan alone was as effective as the combination of cyclophosphamide and doxorubicin in the observed response rates and survival durations [2]. However, the subsequent GOG Protocol # 47 showed that the addition of cisplatin to cyclophosphamide and doxorubicin improved response rates from 46% to 71% with the median duration of survival increasing from 9.5 months to 15.0 months [3]. The fact, however, becomes apparent that a. survival duration of 15 months is not a cure, and the good benefits which cisplatin bestowed on patients with ovarian cancers are limited. The empiric choice of chemotherapeutic agents does not necessarily provide maximal benefit to each patient with ovarian cancer.


Ovarian Cancer Ovarian Cancer Patient Gynecologic Oncology Group Female Reproductive System Human Ovarian Carcinoma Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Griffiths CT: Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. National Cancer Institute Monograph 42:101–104, 1975.PubMedGoogle Scholar
  2. 2.
    Omura GA, Blessing JA, Morrow CP, Buchsbaum HJ, Homesley HD: Follow-up on a randomized trial of melphalan vs. melphalan plus hexamethylmelamine vs. adriamycin plus cyclophosphamide in advanced ovarian adenocarcinoma. Proc Am Soc Clin Oncol 22:470, 1981.Google Scholar
  3. 3.
    Omura GA, Ehrlich CE, Blessing JA: A randomized trial of cyclophosphamide plus adriamycin with or without cisplatinum in ovarian carcinoma. Proc Am Soc Clin Oncol 1:104, 1982.Google Scholar
  4. 4.
    Hamburger AW, Salmon SE: Primary bioassay of human tumor stem cells. Science 197:461–463, 1977.PubMedCrossRefGoogle Scholar
  5. 5.
    Salmon SE, Hamburger AW, Soehnlen B, Durie BGM, Alberts DS, Moon TE: Quantitation of differential sensitivity of human tumor stem cells to anticancer drugs. N Engl J Med 298:1321–1327, 1978.PubMedCrossRefGoogle Scholar
  6. 6.
    Hamburger AW, Salmon SE, Kim MB, et al.: Direct cloning of human ovarian carcinoma cells in agar. Cancer Res 38:3438–3444, 1978.PubMedGoogle Scholar
  7. 7.
    Fogh J, Trempe G: New Human tumor cell lines. In: Human tumor cells in vitro, Fogh J (ed), New York, Plenum Press, 1975, pp 115–159.Google Scholar
  8. 8.
    DiSaia PJ, Morrow M, Kanabus J, Piechal W, Townsend DE: Two new tissue culture lines from ovarian cancer. Gynecol Oncol 3:215–219, 1975.PubMedCrossRefGoogle Scholar
  9. 9.
    Sinna GA, Beckman G, Lundgren E, Nordenson I, Roos G: Characterization of two new human ovarian carcinoma cell lines. Gynecol Oncol 7:267–280, 1979.PubMedCrossRefGoogle Scholar
  10. 10.
    Kimoto T, Ueki A, Nishitani K: A human malignant cell line established from ascites of patient with embryonal carcinoma of ovarium. Acta Pathol Jpn 25:89–98, 1975.PubMedGoogle Scholar
  11. 11.
    Freedman RS, Pihl E, Kusyk C, Gallager HS, Rutledge F: Characterization of an ovarian carcinoma cell line. Cancer 42:2352–2359, 1978.PubMedCrossRefGoogle Scholar
  12. 12.
    Yamada T: The cellular biology of a newly established cell line of human ovarian adenocarcinoma in vitro. Keio J Med 23:53–70, 1974.PubMedCrossRefGoogle Scholar
  13. 13.
    Woods LK, Morgan RT, Quinn LA, Moore GE: Comparison of four new cell lines from patients with adenocarcinoma of the ovary. Cancer Res 39:4449–4459, 1979.PubMedGoogle Scholar
  14. 14.
    Soehnlen B, Young L, Liu R: Standard laboratory procedures for in vitro assay of human tumor stem cells. In: Cloning of human tumor stem cells, Salmon SE (ed), New York, Alan R. Liss, Inc., 1980, pp 331–338.Google Scholar
  15. 15.
    Pavelic ZP, Slocum HK, Rostum YM, Creaven PJ, Karakousis C, Takita H: Colony growth in soft agar of human melanoma, sarcoma, and lung carcinoma cells disaggregated by mechanical and enzymatic methods. Cancer Res 40:2160–2164, 1980.PubMedGoogle Scholar
  16. 16.
    Salmon SE, Buick RN: Preparation of permanent slides of intact soft-agar colony cultures of hematopoietic and tumor stem cells. Cancer Res 39:1133–1136, 1979.PubMedGoogle Scholar
  17. 17.
    Moon TE: Quantitative and statistical analysis of the association between in vitro and in vivo studies. In: Cloning of human tumor stem cells, Salmon SE (ed), New York, Alan R. Liss, Inc., 1980, pp 209–221.Google Scholar
  18. 18.
    Williams TJ, Lieber MM, Podratz KC, Malkasian GD Jr: Soft agar colony formation assay for in vitro testing of sensitivity to chemotherapy of gynecologic malignancies. Am J Obstet Gynecol 145:940–947, 1983.Google Scholar
  19. 19.
    Sikic BI, Evans TL, MacKintosh FR, Smith HS: Human tumor clonogenic assays — studies of growth and drug sensitivity. Proc Amer Assoc Cancer Res 23:186, 1982.Google Scholar
  20. 20.
    Natale RB, Kushner B: Applications of the human tumor cloning assay to ovarian cancer. Proc Amer Assoc Cancer Res 22:156, 1981.Google Scholar
  21. 21.
    Von Hoff DD, Cowan J, Harris G, Reisdorf G: Human tumor cloning: feasibility and clinical correlations. Cancer Chemother Pharmacol 6:265–271, 1981.Google Scholar
  22. 22.
    Ozols RF, Willson JKV, Grotzinger KR, Young RC: Cloning of human ovarian cancer cells in soft agar from malignant effusions and peritoneal washings. Cancer Res 40:2743–2747, 1980.PubMedGoogle Scholar
  23. 23.
    Welander CE, Homesley HD, Jobson VW: In vitro chemotherapy testing of gynecologic tumors: Basic for planning therapy? Am J Obstet Gynecol 147:188–195, 1983.PubMedGoogle Scholar
  24. 24.
    Buick RN, Fry SE, Salmon SE: Effect of host cell interactions on clonogenic carcinoma cells in human malignant effusions. Br J Cancer 41:695–704, 1980.PubMedCrossRefGoogle Scholar
  25. 25.
    Welander CE, Natale RB, Lewis JL Jr: In vitro growth stimulation of human ovarian cancer cells by xenogeneic peritoneal macrophages. J Natl Cancer Inst 69:1039–1047, 1982.PubMedGoogle Scholar
  26. 26.
    Gaines JT, Welander CE, Homesley HD: Improved cloning efficiency in the human tumor stem cell assay using Ficoll gradient separation. Proc Amer Assoc Cancer Res 24:311, 1983.Google Scholar
  27. 27.
    Alberts DS, Chen HSG, Soehnlen B, Salmon S, Surwit EA, Young L: In vitro clonogenic assay for predicting response of ovarian cancer to chemotherapy. Lancet (Aug 16) 340–342, 1980.CrossRefGoogle Scholar
  28. 28.
    Alberts DS, Chen HSG, Young L, et al.: Improved survival for relapsing ovarian cancer patients using the human tumor stem cell assay to select chemotherapy. Proc Amer Soc Clin Oncol 22:462, 1981.Google Scholar
  29. 29.
    Coldman AJ, Goldie JH: A mathematical model of drug resistance in neoplasms. In: Drug and hormone resistance in neoplasia, Vol. 1, Bruchovsky N, Goldie JH (eds), Boca Raton, Florida, CRC Press, Inc., 1982, pp 55–78.Google Scholar
  30. 30.
    Alberts DS, Salmon SE, Surwit EA, Chen HSG, Moon TE, Meyskens FL: Combination chemotherapy in vitro with the human tumor stem cell assay. Proc Amer assoc Cancer Res 22:153, 1981.Google Scholar
  31. 31.
    Sondak VK, Korn El, Morton DL, Kern DH: Absence od in vitro synergy for chemotherapeutic combinations tested in the clonogenic assay. Proc Amer Assoc Cancer Res 24:316, 1983.Google Scholar
  32. 32.
    Day TG, Gallager HS, Rutledge FN: Epithelial carcinoma of the ovary: prognostic importance of histologic grade. National Cancer Institute monograph 42:15–18, 1975.PubMedGoogle Scholar
  33. 33.
    Ozols RF, Garvin AJ, Costa J, Simon RM, Young RC: Histologic grade in advanced ovarian cancer. Cancer Treatment Reports 63:255–263, 1979.PubMedGoogle Scholar
  34. 34.
    Stanley KE: Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 65:25–32, 1980.PubMedGoogle Scholar
  35. 35.
    Volm M: In vitro short-term test to determine the resistance of human tumors to chemotherapy. Cancer 48:2127–2135, 1981.CrossRefGoogle Scholar
  36. 36.
    Epstein LB, Shen JT, Abele JS, Reese CC: Sensitivity of human ovarian carcinoma cells to interferon and other antitumor agents as assessed by an in vitro semisolid agar technique. Ann NY Acad Sci 350:228–244, 1980.PubMedCrossRefGoogle Scholar
  37. 37.
    Salmon SE, Durie BGM, Young L, Liu RM, Trown PW, Stebbing N: Effects of cloned human leukocyte interferons in the human tumor stem cell assay. J Clin Oncol 1:217–225, 1983.PubMedGoogle Scholar
  38. 38.
    Aapro MS, Alberts DS, Salmon SE: Interaction of human leukocyte interferon with vinca alkaloids and other chemotherapeutic agents against human tumors in clonogenic assay. Cancer Chemother Pharmacol, 10:161–166, 1983.PubMedCrossRefGoogle Scholar
  39. 39.
    Welander C, Gaines J, Homesley H, Rudnick S: In vitro synergistic effects of recombinant human interferon alpha2 and doxorubicin on human tumor cell lines. Proc Amer Soc Clin Oncol 2:42, 1983.Google Scholar
  40. 40.
    Dedrick RL, Myers CE, Bungay PM, DeVita VT Jr: Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treatment Reports 62:1–11, 1978.PubMedGoogle Scholar
  41. 41.
    Jones RB, Myers CE, Guarino AM, Dedrick RL, Hubbard SM, DeVita VT: High volume intraperitoneal chemotherapy (2 belly bath’) for ovarian cancer. Cancer Chemother Pharmacol 1:161–166, 1978.PubMedCrossRefGoogle Scholar
  42. 42.
    Howell SB, Pfeifle CL, Wung WE, et al.: Intraperitoneal cisplatin with systemic thiosulfate protecion. Ann Int Med 97:845–851, 1982.PubMedGoogle Scholar
  43. 43.
    Salmon S, Alberts D, Meyskens F: A new concept. In Vitro phase II trial with the human tumor stem cell assay. Proc Am Soc Clin Oncol 21:329, 1980.Google Scholar
  44. 44.
    Slayton R, Petty W, Blessing J: Phase II trial of VP-16 in treatment of advanced ovarian adenocarcinoma. Proc Amer Assoc Cancer Res 20:190, 1979.Google Scholar
  45. 45.
    Shoemaker Rh, Wolpert-Defilippes MK, Makuch RW, Venditti JM: Use of the human tumor clonogenic assay for new drug screening. Proc Amer assoc Cancer Res 24:311, 1983.Google Scholar

Copyright information

© Martinus Nijhoff Publishers, Boston 1985

Authors and Affiliations

  • Charles E. Welander

There are no affiliations available

Personalised recommendations